What Happened

Entera Bio Ltd. presented Phase 1 data at ENDO 2026, comparing single-tablet EB613, multi-tablet EB613, and Forteo®. The study showed that single-tablet EB613 achieved a comparable pharmacokinetic/pharmacodynamic profile to Forteo®, supporting its advancement into Phase 3 trials.

Who Is Affected

Postmenopausal women with osteoporosis or low bone mass are the primary beneficiaries. Healthcare providers seeking more accessible treatment options will also be impacted.

Market Impact

• EB613 could disrupt the osteoporosis market by offering the first oral anabolic treatment.
• Current injectable therapies like Forteo® are underutilized due to administration challenges.
• The aging population and rising healthcare costs make EB613 a timely innovation.

What to Watch

Monitor Entera Bio’s Phase 3 study progress and potential partnerships. Regulatory approvals and market adoption rates will be critical indicators of EB613’s success.